Eli Lilly accelerates cardiometabolic leadership with pivotal new clinical data presentation at EASD 2026
Executive summary: Eli Lilly announced it will present key clinical data from the TRIUMPH-2 and ACHIEVE-4 studies at the EASD 2026 congress, focusing on retatrutide and Foundayo. The results could define the competitive landscape for obesity and type 2 diabetes treatments by demonstrating significant weight loss and A1C improvements.
Who is involved: Eli Lilly, EASD (European Association for the Study of Diabetes).
Likely next: Market reaction to the clinical data presentation and subsequent regulatory filing discussions.
Eli Lilly’s decision to showcase new clinical data for Foundayo, retatrutide and eloraTZP at the EASD 2026 meeting signals a continued push to broaden its metabolic portfolio across multiple administration routes and receptor targets. The presentation comes alongside other notable disclosures at the same conference, including Ascletis’ preclinical discussion of ASC36_35, which claims superior weight‑loss effects compared to an eloralintide/tirzepatide combination, and the launch in UK pharmacies of a new daily diabetes pill that also aids weight reduction. Together, these items illustrate a crowded arena where oral agents, multi‑receptor agonists and fixed‑dose combinations are vying for positioning in the obesity and type‑2 diabetes markets. From a business standpoint, Lilly’s data release could influence near‑term regulatory timelines: positive outcomes may accelerate submission plans for retatrutide or Foundayo, while less‑favorable results might prompt additional studies or a shift in resource allocation. The broader prescription‑drug market, forecast to expand by 62% to roughly $1.7 trillion, provides a sizable backdrop for these innovations, suggesting that any successful product could capture a meaningful share of a rapidly growing segment. Competitors’ parallel advances underscore the need for Lilly to differentiate not only on efficacy but also on dosing convenience and tolerability as it seeks to maintain cardiometabolic leadership.
What's next — scenarios
Base Case: Successful data reinforcement (60%)
Lilly strengthens its market position against competitors like Novo Nordisk.
- Positive A1C and weight loss metrics in the EASD presentation
Upside: Superiority over existing therapies (25%)
Significant market share capture in the oral obesity segment via Foundayo.
- Data showing Foundayo efficacy non-inferior or superior to current market leaders
Downside: Clinical data ambiguity (15%)
Delayed regulatory approvals and slowed investor confidence in the metabolic pipeline.
- Unexpected safety signals or insufficient A1C improvements in the reports
What to watch
- Presentation of TRIUMPH-2 results at EASD 2026
- Presentation of ACHIEVE-4 results at EASD 2026
- FDA/EMA regulatory updates regarding Foundayo and retatrutide
Timeline
- — Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026 (PR Newswire)
Analysis — what this means
Likely next events
- EASD 2026 Annual Meeting (Data presentation)
Sectors affected
- Pharmaceuticals
- Biotechnology
- Healthcare Providers
Regulatory implications
- FDA/EMA review of Foundayo following clinical data
- Compliance with clinical trial reporting standards
Historical parallels
- Novo Nordisk Wegovy oral approval in UK (2024/2025)
- Eli Lilly Foundayo UK authorization (August 2026)
Key entities
Sources
Related cases
- UK launch of oral diabetes pill Foundayo signals new competition in weight‑loss drug market
- Ascletis claims its oral ASC36_35 FDC outperforms eloralintide/tirzepatide combo in preclinical obesity model, positioning it as a potential next‑generation weight‑loss therapy
- Prescription drug sales projected to jump 62% to €1.7 trillion, driven by obesity and autoimmune therapies